Meanwhile, the MAP2K1 and MAP2K2 genes regulate cell proliferation and survival through the MAPK signaling pathway, and their abnormal activation drives tumor growth, metastasis, and drug resistance in lung cancer, making them critical therapeutic targets. This evidence concerns the gene MAP2K1 and lung carcinoma.